Journal of Inherited Metabolic Disease

, Volume 28, Issue 5, pp 665–672

A new protein substitute for adolescents and adults with maple syrup urine disease (MSUD)

Article

Summary

Aim.The aim was to study the efficacy and acceptability of MSUD Express in adolescent and adult patients with maple syrup urine disease (MSUD). Background. There are difficulties associated with current protein substitutes designed for adolescents and adults with MSUD. This can affect their metabolic control. MSUD Express is a new low-volume, nutritionally complete protein substitute, free from leucine, isoleucine and valine and designed specifically for older patients with MSUD. Methods. Four patients with MSUD were included in the trial (aged 16–41 years). Product dosage was 4× 25 g sachets per day, providing 1264 kJ and 72 g amino acids: more than adequately meeting requirements for all micronutrients. Results. At the start of the study, the mean (range) of the previous eight leucine concentrations (on MSUD Aid III) was 564 μmol/L (430–817 μmol/L) and during the study (on MSUD Express) was 382 μmol/L (181–603 μmol/L). The average percentage fall in mean leucine concentrations was 32%. In patients 2, 3 and 4, low leucine levels resulted in an increase in the natural protein allowance per day. MSUD Express was rated as ‘excellent’ or ‘good’ by all patients on the basis of appearance, taste, smell and texture. All patients found the product ‘very easy’ to prepare and found it ‘easy’ or ‘very easy’ to take outside the home. Conclusion. All patients thought the preparation of MSUD Express was ‘very easy’. Metabolic control (mean leucine concentrations) improved in all of the patients. In three patients this meant that an increase in the amount of natural protein in the diet was possible. All patients elected to stay on MSUD Express after the trial period. MSUD Express appears to be an effective and acceptable product, offering an alternative to current protein substitutes available for older people with MSUD.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Clow CL, Reade TM, Scriver CR (1981) Outcome of early and long-term management of classical maple syrup urine disease. Pediatrics 68(6): 856–862.PubMedGoogle Scholar
  2. Dixon M (2001) Disorders of amino acid metabolism, organic acidaemias and urea cycle defects. In: Shaw V, Lawson M, eds. Clinical Paediatric Dietetics, 2nd edn. London: Blackwell Science, 253–262.Google Scholar
  3. Kaplan P, Mazur A, Field M (1991) Intellectual outcome in children with maple syrup urine disease. J Pediatr 119(1 pt 1): 46–50.PubMedGoogle Scholar
  4. MacDonald A, Lilburn M, Cochrane B (2004) A new, low volume protein substitute for teenagers and adults with phenylketonuria. J Inherit Metab Dis 27(2): 127–135.CrossRefPubMedGoogle Scholar
  5. Morton D, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI (2002) Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics 109(6): 1008.CrossRefGoogle Scholar
  6. Nyhan WL, Ozand OT (1998) Maple syrup urine disease. In: Nyhan WL, Ozand OT, eds. Atlas of Metabolic Diseases, 1st edn. London: Chapman and Hall Medical, 138–146.Google Scholar
  7. Ogier de Baulny H, Saudubray JM (2000) Branched-chain organic acidurias. In: Fernandes J, Saudubray JM, Van den Berghe G, eds. Inborn Metabolic Diseases: Diagnosis and Treatment, 3rd revised edn. Heidelberg: Springer-Verlag, 197–212.Google Scholar
  8. Smith I, Cockburn F, Brenton DP, et al (1993) Medical Research Council Working Party on Phenylketonuria. Recommendations on the dietary management of phenylketonuria. Arch Dis Child 68: 426–427.Google Scholar
  9. Snyderman SE (1988) Treatment outcome of maple syrup urine disease. Acta Paediatr Jpn 30(4): 417–424.PubMedGoogle Scholar
  10. Van Wyk K (2000) Specialist dietitian—metabolic disease. Maple Syrup Urine Disease—Practical Dietary Management. Great Ormond Street Hospital for Children NHS Trust, in SHS Inborn Error Review Series No. 10.Google Scholar

Copyright information

© SSIEM and Springer 2005

Authors and Affiliations

  1. 1.The Charles Dent Metabolic Unit, The National Hospital for Neurology {&} NeurosurgeryUniversity College Hospitals NHS TrustLondonUK
  2. 2.The Charles Dent Metabolic UnitThe National Hospital for Neurology and NeurosurgeryLondon

Personalised recommendations